FindTrial
Sign In

Tapentadol nasal spray- a better alternative than intavenous tramadol and diclofenac

Tapentadol nasal spray:a better alternative than conventional nsaids and opioids?

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036432
Enrollment
300
Registered
2021-09-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G891- Acute pain, not elsewhere classified

Interventions

Intervention1: Tapentadol nasal spray: tapentadol nasal spray will be administered and measurement of pain relief in post-op day 1,2,3 Control Intervention1: intravenous diclofenac and intravenous tr

Sponsors

Rajendra Institute of Medical Sciences Ranchi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: UNDERGOING ANY TYPE OF SURGICAL PROCEDURE

Exclusion criteria

Exclusion criteria: PATIENTS OPTING OUT OF STUDY OR HAVING SEVERE CARDIOVASCULAR OR RENAL RISK FACTORS

Design outcomes

Primary

MeasureTime frame
REDUCTION IN POST-SURGICAL PAINTimepoint: REDUCTION IN POST-SURGICAL PAIN measured on day 1, 2 and 3 and overall satisfaction measured on goal attainment scale—

Secondary

MeasureTime frame
overall satisfaction measured on goal attainment scaleTimepoint: at the time of discharge—

Countries

India

Contacts

Public ContactDr Nishith M Paul Ekka

RIMS RANCHI

drnmpekka@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026